Institute of Drug Discovery Technology, Ningbo University, Ningbo, Zhejiang 315211, China.
Department of Pharmacy, the PLA Rocket Force Characteristic Medical Center, Beijing 100088, China.
Curr Med Chem. 2021;28(16):3107-3146. doi: 10.2174/0929867327666201013162144.
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide, with nearly one million new cases and deaths every year. Owing to the complex pathogenesis, hidden early symptoms, rapidly developing processes, and poor prognosis, the morbidity and mortality of HCC are increasing yearly. With the progress being made in modern medicine, the treatment of HCC is no longer limited to traditional methods. Targeted therapy and immunotherapy have emerged to treat advanced and metastatic HCC in recent years. Since Sorafenib is the first molecular targeting drug against angiogenesis, targeted drugs for HCC are continually emerging. Moreover, immunotherapy plays a vital role in clinical trials. In particular, the application of immune checkpoint inhibitors, which have received increasing attention in the field of cancer treatment, is a possible research path. Interestingly, these two therapies generally complement each other at some stages of HCC, bringing new hope for patients with advanced HCC. In this paper, we discuss the research progress of targeted therapy and immunotherapy for HCC in recent years, which will provide a reference for the further development of drugs for HCC.
肝细胞癌（HCC）是全球最常见的恶性肿瘤之一，每年有近 100 万例新发病例和死亡病例。由于发病机制复杂、早期症状隐匿、病情发展迅速、预后不良，HCC 的发病率和死亡率呈逐年上升趋势。随着现代医学的进步，HCC 的治疗不再局限于传统方法。近年来，出现了针对晚期和转移性 HCC 的靶向治疗和免疫治疗。索拉非尼是首个针对血管生成的分子靶向药物，因此 HCC 的靶向药物不断涌现。此外，免疫治疗在临床试验中发挥着重要作用。特别是免疫检查点抑制剂的应用，在癌症治疗领域受到越来越多的关注，是一个可能的研究途径。有趣的是，这两种疗法在 HCC 的某些阶段通常可以互补，为晚期 HCC 患者带来新的希望。本文就近年来 HCC 的靶向治疗和免疫治疗的研究进展进行综述，为 HCC 药物的进一步开发提供参考。
